Chronic obstructive pulmonary disease (COPD) Respiratory Other chronic obstructive pulmonary disease
Conditions
Interventions
Cineole 200 mg (oral) three times per day in addition to basic treatment, for 6 months during winter. Control group received placebo capsules.
Sponsors
MKL Institute of Clinical Research (MKL Institut für Klinische Forschung GmbH) (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients (both males and females) with COPD, at least three exacerbations during the winter months 2. Forced expiratory volume in 1 second (FEV1) greater than 30% and less than 70% of predicted value, increase of FEV1 less than 15% and less than 200 ml after inhalation of beta-agonists 3. Smoker/ex-smoker greater than 10 pack years
Exclusion criteria
Exclusion criteria: 1. Aged less than 40 years and greater than 80 years 2. Asthma bronchiale 3. Comedication with other mucolytics 4. Infection at the beginning of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between exacerbations (number, time, sevrity). The primary and secondary outcomes were assessed at initial visit and after 1, 2 ,3, 4, 5 and 6 months of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Symptoms of COPD (dyspnoea, secretion, cough) 2. Spirometry: FEV1, forced vital capacity (FVC), vital capacity (VC) 3. Quality of life, assessed by the St George's Respiratory Questionnaire (SGRQ) The primary and secondary outcomes were assessed at initial visit and after 1, 2 ,3, 4, 5 and 6 months of treatment. | — |
Countries
Germany
Outcome results
None listed